Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Changing body weight-based dosing to a flat dose for avelumab in metastatic Merkel cell and advanced urothelial carcinoma.

Novakovic AM, Wilkins JJ, Dai H, Wade JR, Neuteboom B, Brar S, Bello CL, Girard P, Khandelwal A.

Clin Pharmacol Ther. 2019 Sep 25. doi: 10.1002/cpt.1645. [Epub ahead of print]

PMID:
31553054
2.

Population Pharmacokinetic Analysis of Bintrafusp Alfa in Different Cancer Types.

Wilkins JJ, Vugmeyster Y, Dussault I, Girard P, Khandelwal A.

Adv Ther. 2019 Sep;36(9):2414-2433. doi: 10.1007/s12325-019-01018-0. Epub 2019 Jul 5.

PMID:
31278692
3.

Nonlinear Mixed-Effects Model Development and Simulation Using nlmixr and Related R Open-Source Packages.

Fidler M, Wilkins JJ, Hooijmaijers R, Post TM, Schoemaker R, Trame MN, Xiong Y, Wang W.

CPT Pharmacometrics Syst Pharmacol. 2019 Sep;8(9):621-633. doi: 10.1002/psp4.12445. Epub 2019 Jul 16.

4.

Time-Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma.

Wilkins JJ, Brockhaus B, Dai H, Vugmeyster Y, White JT, Brar S, Bello CL, Neuteboom B, Wade JR, Girard P, Khandelwal A.

CPT Pharmacometrics Syst Pharmacol. 2019 Jun;8(6):415-427. doi: 10.1002/psp4.12406. Epub 2019 Apr 25.

5.

Data standards for model-informed drug development: an ISoP initiative.

Radivojevic A, Corrigan B, Downie N, Fox R, Fiedler-Kelly J, Liu H, Melhem M, Radke D, Schaefer P, Su J, Swat MJ, Teuscher NS, Thanneer N, Zong A, Wilkins JJ.

J Pharmacokinet Pharmacodyn. 2018 Oct;45(5):659-661. doi: 10.1007/s10928-018-9595-8. Epub 2018 Jul 25. No abstract available.

PMID:
30046963
6.

Open innovation: Towards sharing of data, models and workflows.

Conrado DJ, Karlsson MO, Romero K, Sarr C, Wilkins JJ.

Eur J Pharm Sci. 2017 Nov 15;109S:S65-S71. doi: 10.1016/j.ejps.2017.06.035. Epub 2017 Jul 4. Review.

PMID:
28684136
7.

Thoughtflow: Standards and Tools for Provenance Capture and Workflow Definition to Support Model-Informed Drug Discovery and Development.

Wilkins JJ, Chan P, Chard J, Smith G, Smith MK, Beer M, Dunn A, Flandorfer C, Franklin C, Gomeni R, Harnisch L, Kaye R, Moodie S, Sardu ML, Wang E, Watson E, Wolstencroft K, Cheung S; DDMoRe Consortium.

CPT Pharmacometrics Syst Pharmacol. 2017 May;6(5):285-292. doi: 10.1002/psp4.12171. Epub 2017 May 15.

8.

A drug and disease model for lixisenatide, a GLP-1 receptor agonist in type 2 diabetes.

Wilkins JJ, Dubar M, S├ębastien B, Laveille C.

J Clin Pharmacol. 2014 Mar;54(3):267-78. doi: 10.1002/jcph.192. Epub 2013 Oct 19.

PMID:
24122776
9.

Safety, tolerability, and pharmacokinetics of ribavirin in hepatitis C virus-infected patients with various degrees of renal impairment.

Brennan BJ, Wang K, Blotner S, Magnusson MO, Wilkins JJ, Martin P, Solsky J, Nieforth K, Wat C, Grippo JF.

Antimicrob Agents Chemother. 2013 Dec;57(12):6097-105. doi: 10.1128/AAC.00608-13. Epub 2013 Sep 30.

10.

Emergence of anxiety-like behaviours in depressive-like Cpe(fat/fat) mice.

Rodriguiz RM, Wilkins JJ, Creson TK, Biswas R, Berezniuk I, Fricker AD, Fricker LD, Wetsel WC.

Int J Neuropsychopharmacol. 2013 Aug;16(7):1623-34. doi: 10.1017/S1461145713000059. Epub 2013 Feb 27.

11.

Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients.

Wilkins JJ, Langdon G, McIlleron H, Pillai G, Smith PJ, Simonsson US.

Br J Clin Pharmacol. 2011 Jul;72(1):51-62. doi: 10.1111/j.1365-2125.2011.03940.x.

12.

Modeling disease progression in acute stroke using clinical assessment scales.

Karlsson KE, Wilkins JJ, Jonsson F, Zingmark PH, Karlsson MO, Jonsson EN.

AAPS J. 2010 Dec;12(4):683-91. doi: 10.1208/s12248-010-9230-0. Epub 2010 Sep 21.

13.

Evaluation of the nonparametric estimation method in NONMEM VI: application to real data.

Baverel PG, Savic RM, Wilkins JJ, Karlsson MO.

J Pharmacokinet Pharmacodyn. 2009 Aug;36(4):297-315. doi: 10.1007/s10928-009-9122-z. Epub 2009 Jul 2.

PMID:
19572188
14.

Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption.

Wilkins JJ, Savic RM, Karlsson MO, Langdon G, McIlleron H, Pillai G, Smith PJ, Simonsson US.

Antimicrob Agents Chemother. 2008 Jun;52(6):2138-48. doi: 10.1128/AAC.00461-07. Epub 2008 Apr 7.

15.

Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients.

Wilkins JJ, Langdon G, McIlleron H, Pillai GC, Smith PJ, Simonsson US.

Eur J Clin Pharmacol. 2006 Sep;62(9):727-35. Epub 2006 May 10. Erratum in: Eur J Clin Pharmacol. 2006 Sep;62(9):779.

PMID:
16685561
16.

NONMEMory: a run management tool for NONMEM.

Wilkins JJ.

Comput Methods Programs Biomed. 2005 Jun;78(3):259-67.

PMID:
15899310
17.

Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis.

Langdon G, Wilkins JJ, Smith PJ, McIlleron H.

Int J Tuberc Lung Dis. 2004 Jul;8(7):862-7.

PMID:
15260278
18.
19.

Photo-fission of uranium with possible emission of a beryllium nucleus.

GOWARD FK, TITTERTON EW, WILKINS JJ.

Nature. 1949 Oct 15;164(4172):661. No abstract available.

PMID:
18143358

Supplemental Content

Loading ...
Support Center